Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Remodulin Clear all

Conditions: Liver Transplant
Interventions: treprostinil sodium, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions: Inhaled Treprostinil, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 96
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more

Conditions: Portopulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 1 more

Conditions: Persistent Pulmonary Hypertension of the Newborn
Interventions: IV Remodulin, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 1 Hour to 14 Days
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 14
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 11 more

Conditions: Pulmonary Arterial Hypertension
Interventions: UT-15C SR; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 15 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Phoenix, Arizona • Tucson, Arizona • St Louis, Missouri + 3 more

Conditions: Critical Limb Ischemia
Interventions: treprostinil dienthanolmine sustained release, Placebo; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Pulmonary Arterial Hypertension
Interventions: Remunity Pump for Remodulin; Combination Product
Lead sponsor: United Therapeutics; Industry
Eligibility: 22 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Prospective study assessments; Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more

Conditions: Pulmonary Arterial Hypertension
Interventions: UT-15C (treprostinil diolamine); Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 38
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Inhaled treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 15
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more

Conditions: Pulmonary Arterial Hypertension
Interventions: treprostinil, Crono Five ambulatory pump; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: San Francisco, California • New York, New York • Oklahoma City, Oklahoma

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions: Qutenza (8% capsaicin); Drug
Lead sponsor: University of Rochester; Other
Eligibility: 15 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 90
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 73 more

Conditions: Pulmonary Arterial Hypertension
Interventions: UT-15C SR, treprostinil diethanolamine; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pulmonary Hypertension, Pulmonary Fibrosis
Interventions: Oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 4 more

Conditions: Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Inhaled Treprostinil; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions: Treprostinil diethanolamine, Esomeprazole; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Model 10642 Implantable Intravascular Catheter; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 5 more

Conditions: Pulmonary Hypertension
Interventions: Treprostinil, Standard of Care; Drug · Other
Lead sponsor: Valley Health System; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Paramus, New Jersey

Conditions: Pulmonary Hypertension
Interventions: UT-15; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 8 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 7
States / cities: Torrance, California • Chicago, Illinois • Baltimore, Maryland + 4 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia
Interventions: Inhaled Treprostinil (Tyvaso Nebulizer); Drug
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 40 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Congenital Heart Disease
Interventions: Remodulin; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Los Angeles, California • Columbus, Ohio

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil diethanolamine; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: C16TR, Placebo, Tyvaso®; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Remodulin® to Oral Treprostinil Transition

Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure

Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study

Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)

Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants